Published 16:56 IST, July 10th 2024

Namita Thapar-backed Emcure Pharmaceuticals debuts at 31% premium over issue price

The Emcure Pharma IPO saw significant oversubscription, primarily driven by non-institutional investors on the third day of the bidding process.

Reported by: Business Desk
Follow: Google News Icon
  • share
Emcure Pharmaceuticals IPO 2024
Emcure Pharmaceuticals IPO 2024 | Image: Republic Business
  • Listen to this article
  • 2 min read

10:19 IST, July 10th 2024